The growing general interest surrounding Cannabis sativa L. has led to a renewal in breeding and resulted in an impressive variability of chemotypical characteristics that required the division of cannabis into different recognized chemotypes. The chemotype V has been overlooked in terms of phytochemical composition due to the almost total absence of cannabinoids, on which biomedical attention is focused. Systematic approaches addressing diverse chemotypes are, however, needed to discriminate and define phytochemical aspects beyond cannabinoids. Such thoroughly characterized chemotypes guarantee blinding in controlled studies by mimicking the sensory properties of hemp and may help to unravel the “entourage effect”. Capitalizing on the ability of cannabis to synthesize a large number of non-cannabinoid phenolic compounds, we here investigated, for the first time, the composition of the Ermo chemotype V and identified new compounds: two dihydrophenanthrenes and the methoxy-dihydrodenbinobin. All three compounds suppress pro-inflammatory leukotriene biosynthesis in activated macrophage subtypes by targeting 5-lipoxygenase, but substantially differ in their capacity to elevate the levels of specialized pro-resolving lipid mediators and their precursors in M2 macrophages. We conclude that the discovered compounds likely contribute to the anti-inflammatory properties of Cannabis sativa L. chemotype V and might promote inflammation resolution by promoting a lipid mediator class switch.
Inflammatory responses are orchestrated by a plethora of lipid mediators, and perturbations of their biosynthesis or degradation hinder resolution and lead to uncontrolled inflammation, which contributes to diverse pathologies. Small molecules that induce a switch from pro-inflammatory to anti-inflammatory lipid mediators are considered valuable for the treatment of chronic inflammatory diseases. Commonly used non-steroidal anti-inflammatory drugs (NSAIDs) are afflicted with side effects caused by the inhibition of beneficial prostanoid formation and redirection of arachidonic acid (AA) into alternative pathways. Multi-target inhibitors like diflapolin, the first dual inhibitor of soluble epoxide hydrolase (sEH) and 5-lipoxygenase-activating protein (FLAP), promise improved efficacy and safety but are confronted by poor solubility and bioavailability. Four series of derivatives bearing isomeric thiazolopyridines as bioisosteric replacement of the benzothiazole core and two series additionally containing mono- or diaza-isosteres of the phenylene spacer were designed and synthesized to improve solubility. The combination of thiazolo[5,4-b]pyridine, a pyridinylen spacer and a 3,5-Cl2-substituted terminal phenyl ring (46a) enhances solubility and FLAP antagonism, while preserving sEH inhibition. Moreover, the thiazolo[4,5-c]pyridine derivative 41b, although being a less potent sEH/FLAP inhibitor, additionally decreases thromboxane production in activated human peripheral blood mononuclear cells. We conclude that the introduction of nitrogen, depending on the position, not only enhances solubility and FLAP antagonism (46a), but also represents a valid strategy to expand the scope of application towards inhibition of thromboxane biosynthesis.
Lipidomics-guided screening of unexplored chemical space in natural products provides access to small molecules capable of modifying cellular lipid profiles on a global scale. Here, we show that the meroterpenoid cyclosmenospongine from Spongia sp . shapes the lipid profile of immune cells, favoring anti-inflammatory and pro-resolving over pro-inflammatory lipid mediators. Structural variation revealed derivatives that inhibit leukotriene biosynthesis to varying extents while differentially upregulating pro-resolving lipid mediators, epoxyeicosatrienoic acids, endocannabinoids, and sphingosine-1-phosphate, along with other mediators, both in resting and activated innate immune cells in vitro and in self-resolving murine peritonitis in vivo . Mechanistically, meroterpenoids target 5-lipoxygenase or 5-lipoxygenase-activating protein, promote the translocation of 15-lipoxygenase-1 to cytoplasmatic sites, and inhibit monoacylglycerol lipase. They also redirect arachidonic acid (AA) from neutral lipids to specific phospholipids, while increasing the total concentration of free AA. Furthermore, meroterpenoids reprogram lipid metabolism in immune cells, decreasing the levels of neutral lipids, triacylglycerols, and cholesteryl esters. This shift correlates with a reduced capacity for leukotriene biosynthesis and is mimicked by the inhibition of sterol-O-acyltransferase and diacylglycerol acyltransferase-1/2. In conclusion, specific meroterpenoids exert anti-inflammatory effects by intervening in lipid mediator biosynthesis, prompting structure-controlled switches in lipid mediator classes, among others, through an unexpected link between lipogenesis and inflammation.
Restoring homeostasis in persistent inflammation requires suppressing the inflammatory response and promoting resolution. Currently, no clinically used small molecules intentionally achieve both effects. Endogenous long-chain vitamin E metabolites (LCMs) address inflammation at multiple sites, including pro-inflammatory leukotriene production and cytokine release, thus limiting inflammation. Among LCMs, we here identified ω-carboxylates and ω-alcohols that suppress leukotriene biosynthesis while enhancing the biosynthesis of prostaglandin E2 and specialized pro-resolving mediators, specifically protectins or isomers, proposed to promote inflammation resolution. These LCMs induce a lipid mediator class switch in activated and non-activated human innate immune cells and in a mouse model of self-resolving peritonitis and inhibit ferroptosis. Changes in lipid mediator classes are tightly coordinated between local and systemic sites and follow different kinetics. Mechanistically, LCMs induce polyunsaturated fatty acid release and translocate 15-lipoxygenase-1, a key enzyme in protectin biosynthesis, to particulate locales while also engaging other mechanisms, partially involving cyclooxygenase-2, to increase protectin production. The LCMs also inhibit soluble epoxide hydrolase, reducing the degradation of anti-inflammatory epoxyeicosatrienoic acids, and increase levels of endocannabinoids and dihydroceramides with immunomodulatory and stress-protective functions. These findings provide insights into immunoregulation by tocotrienol metabolites and offer promising lead structures for redirecting lipid mediator profiles from inflammation toward resolution.
Lipidomics‐guided screening of unexplored natural product chemical space provides access to small molecules that globally reprogram cellular lipid profiles. Here, we show that the meroterpenoid cyclosmenospongine from Spongia sp . reshapes immune cell lipidomes, shifting them from pro‐inflammatory toward anti‐inflammatory and pro‐resolving mediators. Structural variation yielded derivatives that context‐dependently inhibit leukotriene biosynthesis to varying extents while upregulating pro‐resolving lipid mediators, epoxyeicosatrienoic acids, endocannabinoids, sphingosine‐1‐phosphate, and others in resting and activated innate immune cells in vitro, as well as in self‐resolving murine peritonitis and fibrosis in vivo. Mechanistically, meroterpenoids target 5‐lipoxygenase or 5‐lipoxygenase‐activating protein, promote 15‐lipoxygenase‐1 translocation to particulate sites, and inhibit monoacylglycerol lipase. They also redirect arachidonic acid from neutral lipids to specific phospholipids while increasing free arachidonic acid levels. Furthermore, meroterpenoids reprogram immune cell lipid metabolism by reducing neutral lipid, triacylglycerol, and cholesteryl ester levels, a shift that correlates with a lower capacity for leukotriene biosynthesis and is phenocopied by inhibiting sterol‐O‐acyltransferase, which catalyzes cholesterol esterification for storage, and diacylglycerol acyltransferase‐1/2, which catalyze the final step in triacylglycerol biosynthesis. In conclusion, specific meroterpenoids exert anti‐inflammatory effects by rewiring lipid mediator biosynthesis through structure‐controlled switches in lipid mediator classes, and an unexpected link between lipogenesis and inflammation.